StockNews.AI
PFE
Investopedia
91 days

Pfizer Inks Up to $6B Deal to Market 3SBio's Cancer Drug Outside China

1. Pfizer agreed to market a Chinese cancer drug globally. 2. The deal is valued at approximately $6 billion. 3. Pfizer pays an upfront fee of $1.25 billion. 4. Drug SSGJ-707 targets several cancer types in clinical trials. 5. Pfizer shares rose slightly ahead of market opening.

3m saved
Insight
Article

FAQ

Why Bullish?

The deal opens new revenue streams for PFE, with a promising drug in trials. Historical collaborations in oncology have often yielded significant market returns.

How important is it?

This deal enhances Pfizer's portfolio and demonstrates its commitment to oncology, impacting investor confidence.

Why Long Term?

The full financial benefits are contingent on drug approvals and future sales milestones, which may take years.

Related Companies

Related News